DOTATATE PET for Meningioma Radiation Planning

Not Applicable

Not yet recruiting

• Conditions: Meningioma

• Registration Number: NCT06937268
• Lead Sponsor: British Columbia Cancer Agency

Brief Summary

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-15
• Study First Submitted QC: 2025-04-15
• Last Update Submitted: 2025-04-15
• Study First Posted: 2025-04-22
• Last Update Posted: 2025-04-22
• Study Start: 2025-06
• Primary Completion: 2026-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Age ≥ 18 years old
• Able and willing to comply with the study procedures
• Intact meningioma requiring definitive radiation
• Post-operative meningioma requiring adjuvant radiation
• No prior radiation therapy or medical therapy directed at the tumour

Exclusion Criteria

• Breastfeeding or pregnancy
• Claustrophobia or inability to lie still in a supine position
• Unwillingness or inability to provide informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Target radiation volume	2 years	The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan

Secondary Outcome Measures

Name	Time	Method
Local control	2 years
Progression-free survival	2 years
Perceived usefulness by radiation oncologist	2 years
Adverse event	2 years
Rate of DOTATATE-scan completion	2 years
Extent of post-operative disease volume compared to MRI	2 years
Overall survival	2 years

Trial Locations

Locations (1)

BC Cancer - Vancouver; 🇨🇦 Vancouver, British Columbia, Canada